Abbott Laboratories 2015 Annual Report Download - page 23

Download and view the complete annual report

Please find page 23 of the 2015 Abbott Laboratories annual report below. You can navigate through the pages in the report by either clicking on the pages listed below, or by using the keyword search tool below to find specific information within the annual report.

Page out of 80

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • 17
  • 18
  • 19
  • 20
  • 21
  • 22
  • 23
  • 24
  • 25
  • 26
  • 27
  • 28
  • 29
  • 30
  • 31
  • 32
  • 33
  • 34
  • 35
  • 36
  • 37
  • 38
  • 39
  • 40
  • 41
  • 42
  • 43
  • 44
  • 45
  • 46
  • 47
  • 48
  • 49
  • 50
  • 51
  • 52
  • 53
  • 54
  • 55
  • 56
  • 57
  • 58
  • 59
  • 60
  • 61
  • 62
  • 63
  • 64
  • 65
  • 66
  • 67
  • 68
  • 69
  • 70
  • 71
  • 72
  • 73
  • 74
  • 75
  • 76
  • 77
  • 78
  • 79
  • 80

Within weeks of being treated with Abbott’s
Absorb naturally dissolving stent for the heart,
Roberto was back on his bike, enjoying the
hills around his home.
Absorb is just one example of the innovation
from our Medical Devices group, which includes
our Vascular, Medical Optics and Diabetes Care
businesses. These organizations share a common
focus on leading-edge technological innovation
that improves outcomes while lowering overall
healthcare costs.
In addition to Absorb, our Vascular business also
oers MitraClip, the world’s first transcatheter
mitral-valve repair device.
In our Vision business, our Tecnis family of
lenses helps people with cataracts see better; our
Catalys Precision Laser System helps surgeons
provide cataract patients with more customized
care; and our iDesign Advanced WaveScan Studio
System measures and maps irregularities of the
eye, creating a personalized LASIK treatment
plan for people with myopia.
In Diabetes Care, our FreeStyle Libre Flash
Glucose Monitoring system continues to gain
acceptance in Europe. FreeStyle Libre is a
revolutionary technology that eliminates the
need for routine finger pricks for people
with diabetes.2
In 2015, we also made excellent progress with
Abbott Ventures, a new organization we’ve
built to help expand the scope of our Devices
business. We’ll use this group to make targeted
investments and strategic acquisitions, to build
our new-product pipeline.
ABSORB
Roberto was treated using Abbott’s Absorb
naturally dissolving stent system, which opens
blocked arteries in the heart before being
absorbed, leaving behind a restored vessel in a
natural state, free of a permanent metal implant.
ABBOTT 2015 ANNUAL REPORT
21